Related Experiment Video
Updated: Apr 15, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
New cardiac and skeletal protein aggregate myopathy associated with combined MuRF1 and MuRF3 mutations
Montse Olivé1, Saba Abdul-Hussein2, Anders Oldfors2
1Institute of Neuropathology, Department of Pathology and Neuromuscular Unit, Department of Neurology, CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Instituto Carlos III, Barcelona, Spain.
Abstract:
Protein aggregate myopathies (PAMs) define muscle disorders characterized by protein accumulation in muscle fibres. We describe a new PAM in a patient with proximal muscle weakness and hypertrophic cardiomyopathy, whose muscle fibres contained inclusions containing myosin and myosin-associated proteins, and aberrant distribution of microtubules. These lesions appear as intact A- and M-bands lacking thin filaments and Z-discs. These features differ from inclusions in myosin storage myopathy (MSM), but are highly similar to those in mice deficient for the muscle-specific RING finger proteins MuRF1 and MuRF3. Sanger sequencing excluded mutations in the MSM-associated gene MYH7 but identified mutations in TRIM63 and TRIM54, encoding MuRF1 and MuRF3, respectively. No mutations in other potentially disease-causing genes were identified by Sanger and whole exome sequencing. Analysis of seven family members revealed that both mutations segregated in the family but only the homozygous TRIM63 null mutation in combination with the heterozygous TRIM54 mutation found in the proband caused the disease phenotype. Both MuRFs are microtubule-associated proteins localizing to sarcomeric M-bands and Z-discs. They are E3 ubiquitin ligases that play a role in degradation of sarcomeric proteins, stabilization of microtubules and myogenesis. Lack of ubiquitin and the 20S proteasome subunit in the inclusions found in the patient suggested impaired turnover of thick filament proteins. Disruption of microtubules in cultured myotubes was rescued by transient expression of wild-type MuRF1. The unique features of this novel myopathy point to defects in homeostasis of A-band proteins in combination with instability of microtubules as cause of the disease.
Insights
This study identifies novel genetic mutations in TRIM63 and TRIM54 causing a new protein aggregate myopathy. The findings highlight the critical roles of MuRF1 and MuRF3 in muscle protein homeostasis and microtubule stability.
Area of Science:
- Muscle physiology and genetics
- Proteinopathies
- Molecular biology
Background:
- Protein aggregate myopathies (PAMs) are muscle disorders marked by protein buildup in muscle fibers.
- A novel PAM presents with proximal muscle weakness and hypertrophic cardiomyopathy, featuring unique protein inclusions.
Purpose of the Study:
- To identify the genetic cause of a novel protein aggregate myopathy.
- To investigate the role of MuRF1 and MuRF3 in the pathogenesis of this myopathy.
Main Methods:
- Sanger sequencing and whole exome sequencing to identify gene mutations.
- Analysis of muscle biopsy samples for protein inclusions and microtubule distribution.
- Functional studies using cultured myotubes.
Main Results:
- Identified mutations in TRIM63 and TRIM54 (encoding MuRF1 and MuRF3) segregated with the disease in a family.
- The proband's phenotype was linked to a homozygous TRIM63 null mutation and a heterozygous TRIM54 mutation.
- Muscle fibers showed inclusions of myosin and associated proteins, aberrant microtubules, and impaired protein turnover.
Conclusions:
- This novel myopathy results from defects in A-band protein homeostasis and microtubule instability.
- MuRF1 and MuRF3 play crucial roles in sarcomeric protein degradation and microtubule stabilization.
- The findings provide insights into the molecular mechanisms underlying protein aggregate myopathies.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Cardiomyopathy I: Introduction and Classification

